BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...therapy company Abeona Therapeutics Inc. (NASDAQ:ABEO) promoted Michael Amoroso, SVP and chief commercial officer to COO.Erytech Pharma S.A....
...plc Dr. Reddy's Laboratories Ltd. Mylan N.V. Rhythm Pharmaceuticals Inc. Silence Therapeutics plc Monte Rosa Therapeutics Inc. Adicet Bio Inc. Abeona Therapeutics Inc. Erytech Pharma S.A. SparingVision...
BioCentury | Apr 25, 2020
Management Tracks

Shawver named Silverback CEO; plus Incyte, Bicycle, Imvax, Chiasma, Aelin, Regenacy and Noscendo

...Sheer will become CSO, a newly created position, on May 1. He was CSO at Erytech Pharma S.A....
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Recombinant proteins Inflammation, endocrine/ metabolic, renal Myovant Sciences Ltd. (NYSE:MYOV) $317.5 $317.5 Peptides Genitourinary, cancer Erytech Pharma S.A....
BioCentury | May 6, 2019
Company News

Management tracks: Batu, Halozyme, FOG

...which Celgene Corp. (NASDAQ:CELG) acquired. Following its decision to split its chairman and CEO roles, Erytech Pharma S.A....
...is also CEO and managing partner at Back Bay Life Science Advisors. BioCentury Staff Batu Biologics Inc. BioVentures Investors Erytech Pharma S.A. FogPharma Halozyme...
BioCentury | Jun 29, 2018
Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

...to treat ALL, and that continued development in the indication would require additional clinical trials. Erytech...
...said it has no plans to continue development of Graspa for acute myelogenous leukemia (AML). Erytech...
...in newly diagnosed AML patients (see "Erytech's Graspa Misses in Phase IIb AML Study" ). Erytech...
BioCentury | Jun 25, 2018
Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

...resubmitted MAA, to focus instead on solid tumor indications where it sees larger market opportunities. Erytech...
...to treat ALL, and that continued development in the indication would require additional clinical trials. Erytech...
...in newly diagnosed AML patients (see "Erytech Sinks After Graspa Miss in AML Study" ). Erytech...
BioCentury | May 18, 2018
Finance

China comes to Europe

...Euronext:PHARM) $414.7 $414.7 Ascendis Pharma A/S (NASDAQ:ASND) $399.3 $459.3 Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) $341.6 $341.6 Erytech Pharma S.A....
BioCentury | Feb 6, 2018
Financial News

EdRIP unveils new €345 million fund

...Therapeutics Inc. (Cambridge, Mass.); and the $125.3 million NASDAQ listing for cancer and endocrine/metabolic play Erytech Pharma S.A....
BioCentury | Feb 6, 2018
Finance

Stepping up in Europe

...from BioDiscovery 5. EdRIP participated in the November NASDAQ listing of cancer and endocrine/metabolic play Erytech Pharma S.A....
BioCentury | Jan 13, 2018
Finance

Choosy investors

...NASDAQ:FLXN) 10/11/17 $140.8 $954.4 $940.0 -2% Protagonist Therapeutics Inc. (NASDAQ:PTGX) 10/11/17 $60.0 $347.4 $426.0 23% Erytech Pharma S.A....
Items per page:
1 - 10 of 83
BioCentury | Nov 5, 2020
Management Tracks

Rosén joins Horizon as CSO and R&D head; plus moves at Boehringer, Dr. Reddy’s, Mylan and more

...therapy company Abeona Therapeutics Inc. (NASDAQ:ABEO) promoted Michael Amoroso, SVP and chief commercial officer to COO.Erytech Pharma S.A....
...plc Dr. Reddy's Laboratories Ltd. Mylan N.V. Rhythm Pharmaceuticals Inc. Silence Therapeutics plc Monte Rosa Therapeutics Inc. Adicet Bio Inc. Abeona Therapeutics Inc. Erytech Pharma S.A. SparingVision...
BioCentury | Apr 25, 2020
Management Tracks

Shawver named Silverback CEO; plus Incyte, Bicycle, Imvax, Chiasma, Aelin, Regenacy and Noscendo

...Sheer will become CSO, a newly created position, on May 1. He was CSO at Erytech Pharma S.A....
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Recombinant proteins Inflammation, endocrine/ metabolic, renal Myovant Sciences Ltd. (NYSE:MYOV) $317.5 $317.5 Peptides Genitourinary, cancer Erytech Pharma S.A....
BioCentury | May 6, 2019
Company News

Management tracks: Batu, Halozyme, FOG

...which Celgene Corp. (NASDAQ:CELG) acquired. Following its decision to split its chairman and CEO roles, Erytech Pharma S.A....
...is also CEO and managing partner at Back Bay Life Science Advisors. BioCentury Staff Batu Biologics Inc. BioVentures Investors Erytech Pharma S.A. FogPharma Halozyme...
BioCentury | Jun 29, 2018
Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

...to treat ALL, and that continued development in the indication would require additional clinical trials. Erytech...
...said it has no plans to continue development of Graspa for acute myelogenous leukemia (AML). Erytech...
...in newly diagnosed AML patients (see "Erytech's Graspa Misses in Phase IIb AML Study" ). Erytech...
BioCentury | Jun 25, 2018
Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

...resubmitted MAA, to focus instead on solid tumor indications where it sees larger market opportunities. Erytech...
...to treat ALL, and that continued development in the indication would require additional clinical trials. Erytech...
...in newly diagnosed AML patients (see "Erytech Sinks After Graspa Miss in AML Study" ). Erytech...
BioCentury | May 18, 2018
Finance

China comes to Europe

...Euronext:PHARM) $414.7 $414.7 Ascendis Pharma A/S (NASDAQ:ASND) $399.3 $459.3 Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) $341.6 $341.6 Erytech Pharma S.A....
BioCentury | Feb 6, 2018
Financial News

EdRIP unveils new €345 million fund

...Therapeutics Inc. (Cambridge, Mass.); and the $125.3 million NASDAQ listing for cancer and endocrine/metabolic play Erytech Pharma S.A....
BioCentury | Feb 6, 2018
Finance

Stepping up in Europe

...from BioDiscovery 5. EdRIP participated in the November NASDAQ listing of cancer and endocrine/metabolic play Erytech Pharma S.A....
BioCentury | Jan 13, 2018
Finance

Choosy investors

...NASDAQ:FLXN) 10/11/17 $140.8 $954.4 $940.0 -2% Protagonist Therapeutics Inc. (NASDAQ:PTGX) 10/11/17 $60.0 $347.4 $426.0 23% Erytech Pharma S.A....
Items per page:
1 - 10 of 83